Previous 10 | Next 10 |
BOSTON and LONDON, Nov. 09, 2020 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced that the company is scheduled to present at the Barclays Gene Editing & Gene Therapy Summit on November 16, 2020 at 11:15 AM ET. A live webcast o...
Gainers: [[VIST]] +17.2%. [[WRE]] +6.5%. [[LUB]] +6.1%. [[MAX]] +5.2%. [[ORTX]] +4.3%.Losers: [[FTSI]] -10.2%. [[AOSL]] -3.3%. [[ACB]] -3.1%. [[LIZI]] -2.9%. [[FTCH]] -2.3%. For further details see: ACB, FTCH, ORTX and LUB among after-hours movers
BOSTON and LONDON, Nov. 05, 2020 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced the presentation of new clinical data at the upcoming 62 nd American Society of Hematology (ASH) Annual Meeting to be held virtually Dec...
Orchard just received a positive node from CHMP for its lead drug candidate. US approval should be next. The stock's low price makes no sense. For further details see: Orchard Therapeutics: An Undervalued Stock With Upcoming Catalysts
Orchard Therapeutics (ORTX): Q3 GAAP EPS of -$0.20 beats by $0.26.Revenue of $2M (+4.2% Y/Y) beats by $1.87M.“Our European commercial team is in place and have executed the activities necessary to launch Libmeldy (if approved) on a country-by-country basis in the first half of 2021,...
Libmeldy TM Receiv es Positive CHMP Opinion for the Treatment of Early-Onset Metachromatic Leukodystrophy (MLD); U.S. IND Application on Track for Year End 2020 Cash and Investments of More Than $200M and Runway into 2022 Frontotemporal de...
Liquidia Technologies(LQDA) -37% on rescheduling special meeting of stockholders and reaffirms recommendation to approve proposed acquisition of RareGen.Air Industries (AIRI) -11%.Orchard Therapeutics (ORTX) -8% to host Virtual R&D Investor Event on Friday, November 13.Mira...
BOSTON and LONDON, Nov. 02, 2020 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced that the company will webcast a virtual R&D event ‘New Horizons in Gene Therapy’ on Friday, November 13, 2020 from 9:00 a.m. to 11:00 a.m...
Gainers: [[TRUE]] +6.2%. [[AR]] +5%. [[BCC]] +4.8%.[[GTHX]] +4.5%. [[SHLX]] +2.7%.Losers: [[ORTX]] -14.6%. [[UUU]] -6.8%. [[MDCA]] -6%. [[NRT]] -4.2%. [[CBAY]] -3%. For further details see: AR, SHLX, CBAY and ORTX among after-hours movers
BOSTON and LONDON, Oct. 22, 2020 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced that the company’s chief executive officer, Bobby Gaspar, M.D., Ph.D., has been appointed to the Alliance for Regenerative Medicine...
News, Short Squeeze, Breakout and More Instantly...
Orchard Therapeutics plc Company Name:
ORTX Stock Symbol:
NASDAQ Market:
Orchard Therapeutics plc Website:
TOKYO, LONDON and BOSTON, May 03, 2024 (GLOBE NEWSWIRE) -- Orchard Therapeutics, recently acquired by Kyowa Kirin with the goal of accelerating the delivery of new gene therapies to patients around the globe, today announced that Bobby Gaspar, M.D., Ph.D., co-founder and chief executive officer, ...
Crescent Energy Company Class A (CRGY) is expected to report $0.21 for Q4 2023 ThredUp Inc. (TDUP) is expected to report $-0.13 for Q4 2023 Wright Investors` Service Holdings Inc (IWSH) is expected to report for Q4 2023 Bridgford Foods Corporation (BRID) is expected to report for Q1 2...
Gene therapy being developed as a one-time treatment to address the underlying cause of the disease by inserting a functional copy of the human IDUA gene into a patient’s own hematopoietic stem cells HURCULES study to enroll 40 patients at clinical sites across the U.S....